Evidence map›Paper›PMID 24300188›Full record

ArticlePharmaceutics2012

Ocular drug delivery for glaucoma management.

Nathan Gooch, Sarah A Molokhia, Russell Condie, Randon Michael Burr, Bonnie Archer, Balamurali K Ambati, Barbara Wirostko

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Trial
  2. Review
  3. Gasotransmitters in Glaucoma: A New Paradigm.Bulletin of pharmaceutical research · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Nanoparticle-hydrogel superstructures for biomedical applications.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Review
  14. Review
  15. Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2019
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nathan GoochDepartment of Bioengineering, University of Utah, Salt Lake City, UT, USA. barbara.wirostko@gmail.com.
Sarah A Molokhia
Russell Condie
Randon Michael Burr
Bonnie Archer
Balamurali K Ambati
Barbara Wirostko

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current glaucoma management modalities are hindered by low patient compliance and adherence. This can be due to highly complex treatment strategies or poor patient understanding. Treatments focus on the management or reduction of intraocular pressure. This is most commonly done through the use of daily topical eye drops. Unfortunately, despite effective therapies, glaucoma continues to progress, possibly due to patients not adhering to their treatments. In order to mitigate these patient compliance issues, many sustained release treatments are being researched and are entering the clinic. Conjunctival, subconjunctival, and intravitreal inserts, punctal plugs, and drug depots are currently in clinical development. Each delivery system has hurdles, yet shows promise and could potentially mitigate the current problems associated with poor patient compliance.

Identifiers

PMID24300188
PMCPMC3834906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.